Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with Cisplatin and Radiation in HNSCC
NCT02949700Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Jan 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in head and neck squamous cell carcinoma (HNSCC), sponsored by Baylor College of Medicine. Primary endpoints: Dose-Limiting Toxicity at 13 weeks and Disease Response Rate at 21 weeks. Started Jan 2017; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02949700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949700.